Semnur Pharmaceuticals, a majority-owned subsidiary of Scilex (SCLX) Holding Company, announced that the shareholders of Denali Capital Acquisition approved the previously announced business combination with Semnur. The Business Combination was approved by Denali’s shareholders at its Extraordinary General Meeting held on September 3, 2025, along with all other proposals presented at the Meeting, each of which were set forth in the definitive proxy statement/prospectus filed by Denali with the U.S. Securities and Exchange Commission on August 13, 2025. The combined company will operate as Semnur Pharmaceuticals, Inc. upon consummation of the Business Combination, which is expected to close in September 2025, subject to satisfaction of customary closing conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCLX:
- Scilex Holding Appoints New CEO Amid Leadership Change
- Scilex CEO Jaisim Shah to resign, Henry Ji to succeed
- Scilex unit, Denali enter purchase agreement for $20M private placement
- Scilex says registration statement on Form S-4 declared effective by SEC
- Scilex files to sell 1.39M shares of common stock for holders